Trial Profile
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary) ; Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms COMBAT; KEYNOTE-202
- Sponsors BioLineRx
- 01 Jan 2023 Status changed from active, no longer recruiting to completed.
- 27 Apr 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 27 Apr 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.